Skip to contentO
OptimizeRx Corp
O
OPRXOptimizeRx Corp Q3 2022 · 10-Q
Revenue$15.09M$15.09M−6.4% vs Q3 2021 Net Income-$3.47M-$3.47MN/M vs Q3 2021 EPS Diluted-$0.19-$0.19— vs Q3 2021 Gross Profit$9,420,771+3.8% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
OptimizeRx Corp · CIK 1448431 · Engraved from SEC EDGAR
Operating Cash Flowderived$3,462,222+1,589.5% Free Cash Flowderived$3,438,890+1,748.7% Margins · derivedGross margin62.4%+6.2 pt vs Q3 2021
Operating margin-24.9%−25.1 pt vs Q3 2021
Net margin-23.0%−23.2 pt vs Q3 2021
ended Sep 30, 2022 · filed Nov 8, 2022 · 39 d after period end